Ovarian cancer, endometrial cancer
Conditions
Interventions
Index test:89Zr-DFO-CN808001 PET/CT
18F-FDG PET/CT
Sponsors
Affiliated Hospital of North Sichuan Medical College
Eligibility
Sex/Gender
Female
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Informed consent must be obtained prior to participation in the study. 2. Female patients = 18 years old. 3. Histologically or cytologically confirmed locally advanced or metastatic ovarian cancer, endometrial cancer. 4. Tissue specimens confirmed by immunohistochemistry to have high target expression (high expression is defined as: IHC H-Score >50 for ovarian cancer; IHC H-Score for endometrial cancer >10). 5. Failure of previous chemotherapy treatment. 6. ECOG score is 0~2 points, and the expected survival time is = 12 weeks. 7. Adequate organ function: bone marrow reserve: neutrophil count (ANC) = 1.5×10^9/L, platelet count = 100×10^9/L, hemoglobin = 90g/L; Liver: total bilirubin (TBIL) = 1.5 times the upper limit of normal (ULN), alanine aminotransferase (ALT) and aspartate aminotransferase (AST) = 3.0×ULN; Kidney: serum creatinine (SCr) = 1.5× ULN. 8. Female subjects in the reproductive period should use effective contraception and have a negative pregnancy test before the start of treatment, or prove that the subject has no possibility of pregnancy.
Exclusion criteria
Exclusion criteria: 1. Is participating in any other clinical trial or receiving an investigational drug. 2. Patients with central nervous system (CNS) metastases who are symptomatic or receiving glucocorticoid therapy to maintain the functional integrity of the nervous system. 3. Patients with other malignancies that may interfere with disease evaluation, patients with a prior history of malignancy but adequate treatment, who have not been treated for more than 3 years before enrollment and have no evidence of recurrence are eligible to participate in the study. 4. Concomitant severe or poorly controlled medical illness, including but not limited to difficult-to-control infection, known active hepatitis B or hepatitis C, severe cardiovascular disease, or other illness that, in the opinion of the investigator, may impair study participation or collaboration. 5. History of physical or psychiatric illness that may interfere with the purpose and evaluation of the study, or any condition judged by the investigator that the patient cannot cooperate with imaging examinations and procedures. 6. Women who are pregnant or breastfeeding, or patients who do not agree to use effective contraception or restrict sexual behavior. 7. Presence of other conditions that the investigator considers unsuitable to participate in the trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Sensitivity;Specificity;Positive prediction rate;Negative prediction rate; | — |
Countries
China
Contacts
Public ContactSuping Li
Affiliated Hospital of North Sichuan Medical College
Outcome results
None listed